CSPG4 and melanoma: Four consistency runs using the optimized protocol for CAR-T cell production proofed the stable production of a sufficient number of CSPG4-CAR-transfected T cells with a low contamination by other cells, a very high transfection efficiency, a high CAR expression, and a high potency to kill melanoma target cells.